Development of a novel class of therapeutics for PTSD treatment and other neurodegenerative disorders

ReST Therapeutics is a French biotech company founded late 2020 that develops breakthrough therapies to treat complex central nervous system disorders, in particular, Post-Traumatic Stress Disorder (PTSD) under its various forms followed by Alzheimer Disease (AD).Our lead candidate - FENM is a novel and proprietary chemical entity (NCE) targeting specifically a subtype of NMDA receptor (involved in synaptic plasticity) in order to facilitate stress release and neuroprotection without triggering adverse side effects of current NMDA targeting drugs.

FENM will enter First-in-Human in June 2023 to initiate the clinical demonstration on PTSD.

ReST is also advancing new compounds to generate a robust library of candidates and generalize its NMDAr subtype modulation platform with the potential to treat other neurologic disorders.

With the EIC support, ReST will bring FENM to clinical PoC (PhIIb) by 2027, secure a partnership with a pharma company and develop new small molecules to expand its pipeline.